PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 29, 2026Nature Biotechnology4 citationsOpen Access

DNA–drug conjugates enable logic-gated drug delivery amplified by hybridization chain reactions

SCSikai ChenMLMiguel López-TenaFRFrancesco Russo

Key Points

  • To explore the potential of DNA–drug conjugates for targeted drug delivery by utilizing hybridization chain reactions.
  • Utilized affibody–DNA and aptamer–DNA conjugates for Boolean logic operations on biomarkers.
  • Triggered hybridization chain reactions (HCRs) by proximity-induced assembly of biomarker binders.
  • Performed fluorescence quantifications to measure delivery efficiency.
  • Tested various drug combinations to evaluate influence on delivery dynamics.
  • Achieved targeted drug delivery with over 100-fold amplification relative to input biomarkers.
  • Identified specific payloads that significantly enhance delivery efficiency.
  • Demonstrated efficacy of combining drugs for improved therapeutic outcomes.

Abstract

Abstract Antibody–drug conjugates enable highly specific delivery of potent cytotoxics to biomarker-expressing cells. In parallel, advances in DNA circuitry and DNA–protein conjugates have allowed programmable integration of molecular inputs and signal amplification via hybridization chain reactions (HCRs). Here we present a system using affibody–DNA and aptamer–DNA conjugates to execute a Boolean logic operation on cell-surface biomarkers, resulting in amplified payload delivery using an HCR of DNA–drug conjugates. Proximity-induced assembly of the biomarker binders generates the initiator that triggers an HCR. The resulting assembly undergoes endocytosis, enabling controlled payload release of drugs conjugated to the DNA with cathepsin-cleavable linkers. We show that DNA–drug conjugates achieve targeted delivery with >100-fold amplification relative to the input biomarkers using fluorescence quantifications. We also identify payloads that strongly influence delivery efficiency and demonstrate delivery of different drug combinations. Finally, we show that biomarker-triggered HCRs can recruit generic antibodies. This modular technology enables tailored combinations of biomarker inputs and drug outputs toward more precise and personalized treatment.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69c8c247de0f0f753b39c835https://doi.org/10.1038/s41587-026-03044-0
Ask AI
Helpful
Bookmark
Share
View Full Paper